Pharma startups like Pharnext are deploying machine learning to search for new therapeutic uses for “off patent” medications.
In the elegant quiet of the café at the Church of Sweden, a narrow Gothic-style building in Midtown Manhattan, Daniel Cohen is taking a break from explaining genetics. He moves toward the creaky piano positioned near the front door, sits down, and plays a flowing, flawless rendition of “Over the Rainbow.”
If human biology is the scientific equivalent of a complicated score, Cohen has learned how to navigate it like a virtuoso. Cohen was the driving force behind Généthon, the French laboratory that in December 1993 produced the first-ever “map” of the human genome. He essentially introduced Big Data and automation to the study of genomics, as he and his team demonstrated for the first time that it was possible to use super-fast computing to speed up the processing of DNA samples.
Scientists worldwide have built on Cohen’s insights, and Cohen himself, an MD with a Ph.D. in immunology, has gone on to success as a researcher and pharma executive. But a quarter-century later, genomics has yielded few of the kinds of paradigm-changing medical breakthroughs that many of its early innovators hoped for. Today, as chief executive and founder of Paris-based drug startup Pharnext, Cohen is striving to understand why that rainbow hasn’t led to a pot of gold.
“Any protein in the body has many different functions, not only one,” he says, returning from the piano to talk with me, “just as you are a person who has many functions in the population, not just one.” The phenomenon Cohen is describing is “pleiotropy,” the capacity of a single gene to have multiple, seemingly unrelated effects. It is one of the complexities of disease that has repeatedly frustrated medical researchers in their quest for therapies for the most stubborn illnesses.
Cohen not only appreciates pleiotropy’s significance: He believes that Pharnext and other drugmakers may soon exploit it—with a powerful boost from artificial intelligence. By embracing the body’s complexity, and by using A.I. to more methodically analyze and map the way the chain reactions of disease sweep through the body, he hopes to develop combinations of drugs tuned to attack a plethora of medical conditions.
Image Credit: Roberto Frankenberg
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
What if you didn’t need surgery to implant a pacemaker on a faulty heart? What if you could control your blood sugar levels without an injection of insulin, or mitigate the onset of a [...]
Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar [...]
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the electrical signals needed to keep those hearts beating. Scientists at Texas Heart Institute (THI) report they have [...]
The lab of Cheryl Kerfeld at Michigan State University has created a synthetic nano-sized factory, based on natural ones found in bacteria. This research could someday lead to new medical, industrial or bioenergy [...]
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0 Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive [...]
Modern light microscopic techniques provide extremely detailed insights into organs, but the terabytes of data they produce are usually nearly impossible to process. New software, developed by a team led by MDC scientist Dr. [...]
It has long been known that gold can be used to do things that philosophers have never even dreamed of. The Institute of Nuclear Physics of the Polish Academy of Sciences in Cracow has [...]
“We’ll have nanobots that… connect our neocortex to a synthetic neocortex in the cloud. Our thinking will be a…. biological and non-biological hybrid.” Ray Kurzweil, TED 2014 UPDATE - August 6 2019 Since [...]
DARPA has awarded funding to six organizations to support the Next-Generation Nonsurgical Neurotechnology (N3) program, first announced in March 2018. Battelle Memorial Institute, Carnegie Mellon University, Johns Hopkins University Applied Physics Laboratory, Palo Alto [...]
Source: Bold Business. Follow them on twitter. Though you may not realize it, more than 40,000 computer-brain interfaces have already been employed in healthcare today. Thus, to say computer-brain interfaces are something new would [...]
It is hard to imagine just how small one nanometer—one-billionth of a meter—really is. Ten hydrogen atoms in a row are one nanometer long. For perspective, consider that a sheet of paper is 75,000 [...]